Mumbai: British scientists conducting a study on superbugs in London have discovered that a highly rare genetic fusion is to blame for the superbug NDM1. This fusion has given NDM1 the power to easily jump between various species of bacteria at a superfast speed, consequently making it drug resistant. The scientists, who first reported the NDM1 last year, have now found that NDM1, by jumping between bacteria strains, can make...
10:06 AM, Feb 13, 2012
New Delhi: Two years after the NDM 1 superbug was first detected in the country, a new report suggests between 100- 200 million Indians might be carrying two deadly forms of superbug, ha-MRSA and ca-MRSA - said to be resistant to all available antibiotics, except for one that has never been tried, because of its potentially fatal side effects. Published in the German news magazine 'Der Spiegel', the report claims...
07:42 AM, Feb 07, 2012
New Delhi: Downplaying the threat of superbug in city hospitals, Delhi Health Minister AK Walia on Friday said the prevalence of the infection is "very low" and cannot be termed "alarming". "There is a very low prevalence of NDM1 infection (New Delhi Metallo beta lactamase) which exists as confirmed in tests conducted in ICUs of a number of hospitals. It is between the range of 0.04 per cent to 0.08...
05:27 PM, Oct 07, 2011
New Delhi: India is hosting a global summit on antibiotic resistance in the Capital this week. This comes post the NDM1 superbug controversy which had put the spotlight on hospital acquired infections. Hospital acquired infections are a dangerous trend that has doctors in India worried. Dr Gaurav Gupta said, "We may treat the patient for the disease he has - but he may die of the infection he got inside...
08:51 AM, Oct 03, 2011
London: For the first time, scientists have found a "superbug" strain of gonorrhoea, resistant to all recommended antibiotics, which they fear could turn a once easily treatable sexually-transmitted disease into a global public health threat. The new strain of the disease, called H041, was found in Japan and leaves doctors with no other option than to try untested medicines to combat it. The analysis of the strain showed that it...
06:21 PM, Jul 11, 2011
New Delhi: In a major development on the fight against the NDM-1 superbug, a Swiss company, Basilea Pharmaceutical, has announced that its un-named drug has proved effective against the bacteria in lab tests. Currently the NDM-1 bacteria is resistant to all known forms of antibiotics. The New Delhi Superbug (NDM-1 bacteria) has been found in water samples in the capital, according to a study published in the Lancet Infectious Diseases...
09:11 AM, May 10, 2011
Mumbai: After the panic the Lancet article about the NDM-1 superbug created in the Capital, an ongoing two month long study being carried out by Pune's Sassoon Hospital and the National Centre of Cell Sciences has alarming findings. Taking blood and urine samples of more than 3000 patients, scientists at Sassoon Hospital found multi-drug resistance in 66 per cent people and 181 were resistant to the highest level of antibiotics,...
09:51 AM, Apr 29, 2011
Mumbai: Reports on the NDM 1 super-bug have not gone down well with the Health Ministry but have brought our attention to the need for a policy to regulate antibiotic use, to curb drug-resistance in bacteria. And now, the 13 member task force, set up by the Health Ministry, has completed its draft National Policy for Containment of Antibiotic Resistance which is waiting for Health Minister Gulam Nabi Azad's approval....
08:46 AM, Apr 21, 2011
Mumbai: Reports on the NDM 1 super-bug have not gone down well with the Health Ministry but have brought our attention to the need for a policy to regulate antibiotic use, to curb drug-resistance in bacteria. And now, the 13 member task force, set up by the Health Ministry, has completed its draft National Policy for Containment of Antibiotic Resistance which is waiting for Health Minister Gulam Nabi Azad's approval. ...
08:46 AM, Apr 21, 2011
Watch the day's top stories on India @ 9 with Rajdeep Sardesai. ...
11:39 PM, Apr 13, 2011
Dr R Laxminarayan and Dr Devi Shetty speak to CNN-IBN about Lancet Journal's NDM-1 superbug study. ...
10:02 PM, Apr 13, 2011
New Delhi: The Indian government has reacted strongly to a study published in the Lancet Journal for Infectious Diseases that tracks the NDM1-superbug to water samples in Delhi. Delhi Chief Minister Sheila Dikshit on Wednesday chaired a high level meeting and reiterated there is no cause for concern and yet has now been forced to set up a six month study of their own. The study has been making the...
08:42 PM, Apr 13, 2011
New Delhi: After denying the existence of NDM-1 superbug in water in Delhi, ever since it was first mentioned in the Lancet Infectious Diseases journal, the government authorities have finally decided to conduct their own studies. The National Centre for Disease Control has planned to conduct a study on the drug-resistant bacteria. A high level meeting was held with top officials of NDMC, MCD and the Director General of Health...
03:29 PM, Apr 12, 2011
The government has formed a scientific committee to look into the findings of the study. It is also working on the National Antibiotic Policy which includes restrictions on usage of third and fourth generation antibiotics, continuous monitoring of drug resistance cases and over the counter sale of antibiotics in pharmacies. ...
09:18 AM, Apr 11, 2011
displayed with permission. Use of the CNN name and/or logo on or as part of CNN-IBN does not derogate from the intellectual property rights of Cable News Network in respect of them.
Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.
Disclaimer: TV18 Broadcast Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at www.sebi.gov.in and the websites of the Lead Managers at www.icicisecurities.com and www.rbs.in Investors should note that investment in equity shares involves a high degree of risk and are requested to refer to "Risk Factors" in the Draft Letter of Offer. The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S under the US Securities Act) except in a transaction exempt from the registration requirements of the US Securities Act and in accordance with any applicable U.S. state securities laws.
